Sarepta Therapeutics (SRPT) Cash from Investing Activities (2010 - 2026)

Sarepta Therapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$134.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 53.85% year-over-year to -$134.4 million; the TTM figure through Mar 2026 stood at $226.4 million (down 7.8% YoY), while the FY2025 annual figure was $69.6 million, down 90.78% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$134.4 million, down from $96.2 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $764.1 million in Q4 2024, with the low at -$785.8 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is $9.8 million (2022), against an average of -$30.7 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities plunged 1201.37% in 2023, then surged 1651.49% in 2024.
• Sarepta Therapeutics' Cash from Investing Activities stood at $9.8 million in 2022, then sank by 756.98% to -$64.4 million in 2023, then surged by 1287.29% to $764.1 million in 2024, then slumped by 87.41% to $96.2 million in 2025, then tumbled by 239.69% to -$134.4 million in 2026.
• Business Quant data shows SRPT's Cash from Investing Activities at -$134.4 million in Q1 2026, $96.2 million in Q4 2025, and $232.4 million in Q3 2025.